Fachbereich
HOSPITAL UNIVERSITARIO RUBER
Publikationen (62) Publikationen, an denen Forscher/innen teilgenommen haben
2023
-
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
Cancer Research Communications, Vol. 3, Núm. 9, pp. 1853-1861
-
A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer
Frontiers in Oncology, Vol. 13
-
Absence of Myocardial Involvement After SARS-CoV-2 Vaccination in Asymptomatic Adolescents
Journal of Cardiovascular Translational Research
-
Alopecia en supervivientes de cáncer de mama en tratamiento con terapia hormonal
Más dermatología, Núm. 42, pp. 11-12
-
Ambulatory surgery for chronic venous insufficiency using radiofrequency thermoablation: quality and satisfaction
Cirugia y Cirujanos (English Edition), Vol. 91, Núm. 5, pp. 672-677
-
Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response
Frontiers in Immunology, Vol. 14
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795
-
Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
International Journal of Molecular Sciences, Vol. 24, Núm. 15
-
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
The New England journal of medicine, Vol. 388, Núm. 22, pp. 2058-2070
-
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial
JAMA Network Open, Vol. 6, Núm. 4, pp. E235822
-
Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors
Molecular Cancer, Vol. 22, Núm. 1
-
Clinical characterization and treatment outcomes of follicular cutaneous immune–related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study
Journal of the American Academy of Dermatology, Vol. 88, Núm. 3, pp. 718-720
-
Comparative Cardiac Magnetic Resonance-Based Feature Tracking and Deep-Learning Strain Assessment in Patients Hospitalized for Acute Myocarditis
Journal of Clinical Medicine, Vol. 12, Núm. 3
-
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
Cancers, Vol. 15, Núm. 14
-
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management
International Journal of Dermatology, Vol. 62, Núm. 8, pp. 1020-1025
-
Directional Atherectomy With Antirestenotic Therapy Versus PTA/Supera Stenting for Popliteal Artery Lesions: A Propensity-Matched Analysis
Journal of Endovascular Therapy
-
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases
Melanoma research, Vol. 33, Núm. 2, pp. 155-158
-
ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
Molecular Oncology, Vol. 17, Núm. 10, pp. 2000-2016
-
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659
-
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
The Lancet Child and Adolescent Health, Vol. 7, Núm. 3, pp. 180-189